Get the Stockscreener App
103.50
0.13%
0.13
Pre-market:
103.50
Exact Sciences Corp stock is traded at $103.50, with a volume of 2.29M.
It is up +0.13% in the last 24 hours and up +1.20% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$103.37
Open:
$103.33
24h Volume:
2.29M
Relative Volume:
0.74
Market Cap:
$19.76B
Revenue:
$3.08B
Net Income/Loss:
$-986.58M
P/E Ratio:
-19.47
EPS:
-5.3172
Net Cash Flow:
$292.08M
1W Performance:
+0.22%
1M Performance:
+1.20%
6M Performance:
+101.32%
1Y Performance:
+112.18%
1-Day Range:
$103.25
$103.55
1-Week Range:
$102.95
$103.55
52-Week Range:
$38.81
$103.67
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
103.50 | 19.73B | 3.08B | -986.58M | 292.08M | -5.3172 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Mizuho | Outperform → Neutral |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
CSLLY or EXAS: Which Is the Better Value Stock Right Now? - Yahoo! Finance Canada
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year - BioSpace
EXACT SCIENCES CORP (NASDAQ:EXAS) Shows Strong Technical and Fundamental Momentum - ChartMill
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration - BioSpace
Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026? - AD HOC NEWS
Exact Sciences (NASDAQ: EXAS) EVP exercises 3,900 options, 1,913 shares withheld - Stock Titan
Exact Sciences (EXAS) CEO reports RSU vesting and tax-withheld share dispositions - Stock Titan
KeyCare, Inc. announced that it has received $27.4 million in funding from a group of investors - marketscreener.com
Exact Sciences Corporation $EXAS Shares Sold by Fox Run Management L.L.C. - MarketBeat
EXAS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pentwater Capital Management LP's Exact Sciences Corp(EXAS) Holding History - GuruFocus
[Form 4] EXACT SCIENCES CORP Insider Trading Activity - Stock Titan
EXACT Sciences (EXAS) HR EVP awarded 23,224 RSUs in new grant - Stock Titan
Exact Sciences (EXAS) grants SVP Herriott 20,321 restricted stock units - Stock Titan
EXACT Sciences (EXAS) CEO receives major RSU grant and tax-share withholding - Stock Titan
Exact Sciences (EXAS) awards 28,063 restricted stock units to EVP Baranick - Stock Titan
Exact Sciences (NASDAQ: EXAS) EVP receives 38,707 restricted stock units - Stock Titan
Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval - Yahoo Finance
December 18th Options Now Available For EXACT Sciences (EXAS) - Nasdaq
Market Outlook: Is Exact Sciences Corporation showing insider buyingJuly 2025 Selloffs & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Abbott Labs Increases Dividends for 54 Years, Acquires Exact Sciences - Intellectia AI
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time - The Motley Fool
Abbott offers $20B in notes to finance Exact Sciences acquisition - MassDevice
Abbott Laboratories (ABT) sells $20B of notes to finance Exact Sciences acquisition - Stock Titan
Exact Sciences stock hits 52-week high at $103.55 By Investing.com - Investing.com India
Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal - Bloomberg
Abbott lines up one of the year's biggest bond sales at $20B - Crain's Chicago Business
Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition - Quiver Quantitative
Exact Sciences Stockholders Approve Abbott Merger as Executive Pay Proposal Fails at Special Meeting - Yahoo Finance
Exact Sciences (NASDAQ:EXAS) Hits New 52-Week HighTime to Buy? - MarketBeat
Abbott kicks off bond sale for Exact Sciences deal - Modern Healthcare
Exact Sciences stock hits 52-week high at $103.55 - Investing.com
Abbott Laboratories Commences 8-Part Bond Sale Tied to Exact Sciences Acquisition, Bloomberg Reports - marketscreener.com
Exact Sciences shareholders approve merger with Abbott Laboratories By Investing.com - Investing.com Nigeria
Exact Sciences (EXAS) Shareholders Approve Abbott Acquisition - GuruFocus
Exact Sciences shareholders approve merger with Abbott Laboratories - Investing.com
Exact Sciences stockholders approve acquisition by Abbott - marketscreener.com
Exact Sciences shareholders approve Abbott acquisition - Investing.com
Exact Sciences Shareholders Approve Acquisition by Abbott Laboratories - marketscreener.com
Exact Sciences shareholders approve $105 per share Abbott acquisition - StreetInsider
Exact Sciences Stockholders Approve Acquisition by Abbott - The Chronicle-Journal
Exact Sciences Corp.: The Quiet Cancer-Test Stock Everyone’s Watching - AD HOC NEWS
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up - The Globe and Mail
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock - Yahoo Finance
Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation $EXAS is Eagle Health Investments LP's 10th Largest Position - MarketBeat
Assessing Exact Sciences (EXAS) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
How The Abbott Offer Is Rewriting The Story For Exact Sciences (EXAS) - Yahoo Finance
How Investors May Respond To Exact Sciences (EXAS) Narrowing Losses And Oncotype DX Milestone - Yahoo Finance
Exact Sciences Earnings: Strong Momentum to Finish the Year Before Abbott Acquisition Closes - Morningstar
Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports - MSN
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):